Vaccine for Oncology is under clinical development by CAS-Lamvac Biotech and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase II drugs for Thyroid Cancer have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vaccine for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine for Oncology overview
Plasmodium immunotherapy is under development for the treatment of non-small cell lung cancer, advanced breast cancer, advanced liver cancer, colorectal cancer, gastric cancer, sarcomas, prostate cancer, ovarian cancer, brain tumor and thyroid cancer. The drug candidate is developing based on recombinant plasmodium which is used for expressing exogenous gene. This gene comprises an antigen gene, a therapeutic agent gene, an immune regulator gene or a peptide gene.
For a complete picture of Vaccine for Oncology’s drug-specific PTSR and LoA scores, buy the report here.